Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Objectives:
- To determine intraperitoneal (IP) progression free survival after optimal debulking and
heated intraperitoneal chemotherapy (HIPEC) with cisplatin in patients with IP spread of
adrenocortical cancer.
- Determine morbidity of this procedure in this patient population.
- Determine the impact of surgery and HIPEC on quality of life (QOL) and hormone excess.
- Examine patterns of recurrence (local versus systemic).
- Determine overall survival after optimal debulking and HIPEC in patients with IP spread of
adrenocortical cancer.